Hansoh Pharmaceutical Group CoHNSPF 90 Pretax Margin % is 37.69% as of Dec. 2025, which is 11% above its 10-year median of 33.89. GuruFocus rates HNSPF with a GF Score™ of 90/100 and a GF Value™ of $3.00 (Modestly Overvalued). Among 954 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 96.44% on this metric.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Pretax Margin % or its related term are showing as below:
HNSPF'
s Pretax Margin % Range Over the Past 10 Years
Min: 29.9 Med: 33.89 Max: 43.59
Current: 43.56
HNSPF's Pretax Margin % is ranked better than 96.44% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs HNSPF: 43.56
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Hansoh Pharmaceutical Group Co Pretax Margin % Related Terms
Hansoh Pharmaceutical Group Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co Pretax Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co (HNSPF) has a Pretax Margin % of 37.69% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 11% above median its historical median of 33.89. Over the past decade, Hansoh Pharmaceutical Group Co's Pretax Margin % has ranged from 29.90 to 43.59. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #34 out of 954 companies in the Drug Manufacturers industry, placing it in the top 3.6%.
Is Hansoh Pharmaceutical Group Co's Pretax Margin % too high?
Hansoh Pharmaceutical Group Co's current Pretax Margin % of 37.69% is 11% above median its 10-year median of 33.89. Over the past 10 years, this metric has ranged from a low of 29.90 to a high of 43.59. The Drug Manufacturers industry median Pretax Margin % is 7.30. Hansoh Pharmaceutical Group Co's value of 37.69% is 416.7% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #34 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #34 out of 954 companies for Pretax Margin %. This places Hansoh Pharmaceutical Group Co in the top 4% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.30. Hansoh Pharmaceutical Group Co's value of 37.69% is 416.7% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own Pretax Margin % has ranged from 29.90 to 43.59 over the past decade. While the company's 10-year median is 33.89 vs. the industry median of 7.30, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current Pretax Margin % of 37.69% is 416.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current Pretax Margin % is 37.69%, which is 11% above median its own 10-year median of 33.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $3.83 — trading 27.5% above its estimated fair value. The current Pretax Margin % is 37.69%, which is 11% above median its 10-year median of 33.89 and 416.7% above the Drug Manufacturers industry median of 7.30. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Pretax Margin % is 37.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 27.5% above its estimated GF Value™ of $3.00.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
Pretax Margin %: 37.69% (11% above median its 10-year median of 33.89)
GF Value™: $3.00 vs. price of $3.83 (27.5% above fair value)
Industry Position: 416.7% above the Drug Manufacturers median (#34 of 954)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score
Get the complete analysis for HNSPF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
